Use and safety of remdesivir in kidney transplant recipients with COVID-19

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Buxeda, Anna
• dc.contributor.author Arias Cabrales, Carlos Enrique
• dc.contributor.author Pérez-Sáez, María José
• dc.contributor.author Pascual, Julio (Pascual Santos)
• dc.contributor.author Crespo Barrio, Marta
• dc.date.accessioned 2022-03-29T06:41:57Z
• dc.date.available 2022-03-29T06:41:57Z
• dc.date.issued 2021
• dc.description.abstract Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
• dc.format.mimetype application/pdf
• dc.identifier.citation Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Cacho J, Cabello Pelegrin S, Melilli E et al. Use and safety of remdesivir in kidney transplant recipients with COVID-19. Kidney Int Rep. 2021 Sep;6(9):2305-15. DOI: 10.1016/j.ekir.2021.06.023
• dc.identifier.doi http://dx.doi.org/10.1016/j.ekir.2021.06.023
• dc.identifier.issn 2468-0249
• dc.identifier.uri http://hdl.handle.net/10230/52789
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Kidney Int Rep. 2021 Sep;6(9):2305-15
• dc.rights © 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword SARS-CoV2l
• dc.subject.keyword Acute kidney injury
• dc.subject.keyword Immunosuppression
• dc.subject.keyword Kidney transplantation
• dc.subject.keyword Remdesivir
• dc.title Use and safety of remdesivir in kidney transplant recipients with COVID-19
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion